Candel Therapeutics, Inc. (NASDAQ:CADL – Get Free Report) major shareholder Estuardo Aguilar-Cordova sold 1,800 shares of the firm’s stock in a transaction dated Thursday, October 3rd. The shares were sold at an average price of $6.85, for a total value of $12,330.00. Following the transaction, the insider now owns 959,873 shares of the company’s stock, valued at $6,575,130.05. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Major shareholders that own more than 10% of a company’s stock are required to disclose their transactions with the SEC.
Candel Therapeutics Stock Down 0.9 %
Shares of CADL opened at $6.65 on Friday. The company has a debt-to-equity ratio of 1.66, a quick ratio of 1.62 and a current ratio of 1.62. The stock has a market capitalization of $197.88 million, a PE ratio of -5.19 and a beta of -0.95. The company’s 50-day simple moving average is $6.25 and its 200-day simple moving average is $6.48. Candel Therapeutics, Inc. has a 1 year low of $0.66 and a 1 year high of $14.30.
Candel Therapeutics (NASDAQ:CADL – Get Free Report) last announced its earnings results on Tuesday, August 13th. The company reported ($0.74) earnings per share for the quarter. Analysts forecast that Candel Therapeutics, Inc. will post -0.91 earnings per share for the current fiscal year.
Institutional Trading of Candel Therapeutics
About Candel Therapeutics
Candel Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. It develops CAN-2409, which is in Phase II clinical trials for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma.
Read More
- Five stocks we like better than Candel Therapeutics
- The How and Why of Investing in Gold Stocks
- 3 Small-Cap Stocks on the Way to Bigger and Better Days
- Trading Halts Explained
- MarketBeat Week in Review – 9/30 – 10/4
- Uptrend Stocks Explained: Learn How to Trade Using Uptrends
- Top Streaming Companies: Who’s Winning the Battle?
Receive News & Ratings for Candel Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Candel Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.